7. Cooperative Ua Lsp - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.

Role
10%+ Owner
Signature
By LSP 7 Management B.V., its director, By /s/ Martijn Kleijwegt, Managing Director
Issuer symbol
EVMN on NYSE
Transactions as of
05 Nov 2025
Net transactions value
$0
Form type
3
Filing time
05 Nov 2025, 20:12:12 UTC
Next filing
12 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LSP 7 Cooperative UA 10%+ Owner JOHANNES VERMEERPLEIN 9, AMSTERDAM, NETHERLANDS By LSP 7 Management B.V., its director, By /s/ Martijn Kleijwegt, Managing Director 05 Nov 2025 0001876264

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVMN Series A Preferred Stock 05 Nov 2025 Common Stock 1,947,477 Direct F1, F2
holding EVMN Series B Preferred Stock 05 Nov 2025 Common Stock 646,587 Direct F2, F3
holding EVMN Series C Preferred Stock 05 Nov 2025 Common Stock 773,069 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ()"IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2 The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.
F3 The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
F4 The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.